Innovation in Transplantation

For over 100 years, CSL Behring has put patients first by delivering on its promise to discover and develop innovative life-changing therapies to address many of the world’s most serious and rare disorders. We’re now bringing that same commitment to transplantation. Our immediate mission is to offer new hope to kidney transplant recipients by investigating new therapies to address antibody-mediated rejection (ABMR) and improve patient outcomes.

Learn more about chronic active ABMR

Imagine Trial Tools

Actively Recruiting

IMAGINE is an ongoing, Phase 3, multicenter, double-blind, placebo-controlled trial to evaluate clazakizumab (a humanized monoclonal antibody that binds to IL-6) in 350 adult kidney transplant recipients with chronic active ABMR.

Access IMAGINE trial information on

More tools to come.

Please check back for updates.

Video Library

Chronic active ABMR is an important cause of late allograft failure after kidney transplantation. There are currently no FDA‑approved therapies to treat this process of rejection. It is the responsibility of the transplant community to generate evidence‑based medicine to make an impact on the lives of our patients and prolong the function of the transplanted graft. The IMAGINE trial provides that opportunity, and uses change in eGFR as a surrogate endpoint for long‑term allograft outcomes.

Arjang Djamali, MD, Chairman, Department of Medicine, Maine Medical Center

Congress Activities

American Transplant Congress (ATC) 2023; June 3-7 in San Diego, California

CSL Behring proudly supports the future of transplant medicine research
On Tuesday, June 6, 2023, Dr Ricardo Mora Cartin, PhD, a post-doctoral researcher at The University of Chicago, was recognized as a recipient of a career development Research Grant Award from CSL Behring to conduct his research: “Addressing Vulnerabilities to the Maintenance of Transplantation Tolerance Using a Bacterial Infection Model.” CSL Behring is proud to support Dr Cartin’s research and its potential benefits to the field of transplant medicine.
The CSL Behring booth showcased the IMAGINE trial
The CSL Behring booth at ATC 2023 featured the IMAGINE trial – an ongoing, Phase 3, multicenter, double-blind, placebo-controlled trial in adult kidney recipients with chronic active ABMR.

Please provide some basic information to access this content.